Navigation Links
Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
Date:11/20/2013

DUBLIN, Nov. 20, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its participation at the 25th Annual Piper Jaffray Healthcare Conference in New York, NY.

Bruce C. Cozadd, chairman and chief executive officer, will provide a corporate overview on Tuesday, December 3, at 8:30 a.m. EST / 1:30 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
2. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
3. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
4. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
5. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
6. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
7. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
8. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
9. Biopharmaceuticals - A Global Market Overview
10. Star Scientific and Rock Creek Pharmaceuticals Announce the Publication of a Peer-Reviewed Article about the ASAP Clinical Trial Showing Immune System Support in Hashimotos Thyroiditis
11. Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadylâ„¢, ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With ... a trusted supplier in the weighing industry, to extending its expertise across the entire ... reactions, immunoassays, hybridizations and more, allowing for its customers to 'Do More' ...
(Date:6/19/2017)... ... 19, 2017 , ... As Vice President, Product Services, Mr. ... implementation, support, and client process and SOP development. , Mr. Guinter brings a ... roles for service providers and top-tier pharmaceuticals, and as an independent consultant supported ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... Tunnell ... for over 50 years. One of the biggest challenges faced by life sciences, biotech ... regulatory affairs services team is Kati Abraham , who is well known in ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):